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Abstract In the most common surgical procedure for perihilar cholangiocarcinoma, the margin status of the proximal bile duct is
determined at the final step. Our procedure, the transhepatic hilar approach, confirms a cancer-negative margin status of the
proximal bile duct first. We first performed a partial hepatic parenchymal transection to expose the hilar plate, and then transected
the proximal bile duct to confirmmargin status. Then, divisions of the hepatic artery and portal vein of the future resected liver are
performed, followed by the residual hepatic parenchymal transection. The transhepatic hilar approach offers a wide surgical field
for safe resection and reconstruction of the portal vein in the middle of the hepatectomy. We reviewed 23 patients with perihilar
cholangiocarcinoma who underwent major hepatectomy using our procedure from 2011 to 2015. A combined vascular resection
and reconstruction was carried out in 14 patients (60.9%). R0 resection was achieved in 17 patients (73.9%), and the overall 3-
year survival rate was 52.9% (median survival time 52.4 months). The transhepatic hilar approach is useful and practicable
regardless of local tumor extension, enabling us to determine tumor resectability and perform safe resection and reconstruction of
the portal vein early in the operation.
Keywords Perihilar cholangiocarcinoma . Transhepatic hilar
approach . Portal vein resection
Introduction
Surgery for perihilar cholangiocarcinoma demands precise
preoperative evaluation and management by very skilled
hepatobiliary surgeons. In the past two decades, advances in
diagnostic and surgical techniques have improved surgical
outcomes and survival rates.1 R0 resection is an important
factor for achieving a good prognosis for perihilar
cholangiocarcinoma.2 This demands not only a major
hepatectomy with caudate lobectomy but also suitable
skeletonization and treatment of the hepatic artery, portal vein,
and bile duct individually. Bismuth described two basic pro-
cedures for a typical hepatectomy. One consisted of hepatec-
tomy with preliminary vascular control, first performed by
Honjo of Kyoto University in 1949. The other was hepatecto-
my by primary parenchymatous transection, which began
with the opening of the parenchyma along the line of the
scissura described by Ton That Tung.3 Using the same con-
cept as primary parenchymatous transection, Miyazaki et al.
recently reported the usefulness of the transhepatic approach
for hilar cholangiocarcinoma, in which extensive hilar bile
duct resection was performed without excision of any liver
parenchyma. This was appropriate for patients with liver dys-
function for whom major hepatectomy was contraindicated.4
This approach offers a sufficient surgical view to visualize the
hilar bile duct and an easy approach to the portal vein and
hepatic artery after partial parenchymal division. In perihilar
cholangiocarcinoma, the critical aspect for curative resection
is the cut margin of the remnant liver, including the hepatic
artery, portal vein, and bile duct. It is preferable to determine
the resectability and possibility of reconstruction of the portal
vein and/or hepatic artery early in the operation. To achieve
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this, in early 2011, we modified a primary hepatic parenchy-
mal transection technique and developed a new operative pro-
cedure with major hepatectomy for perihilar cholangiocarci-
noma, called the transhepatic hilar approach (THA). Here, we
report our experience using the THA technique and our asso-
ciated results.
Materials and Methods
Between January 2011 and December 2015, 23 patients with
perihilar cholangiocarcinoma underwent major hepatic resec-
tion with caudate lobectomy using the THA followed by hep-
atectomy with curative intent at our institution. The patients
consisted of 13 men and 10 women, with an average age of
70 years (range 51–87 years). Multidetector-row computed
tomography (MDCT), endoscopic retrograde cholangiogra-
phy (ERC), and intraductal ultrasonography (IDUS) were
used in all patients for preoperative tumor staging. Tumor
and negative biopsies by ERC were used for confirming diag-
nosis and definition of biliary cancer invasion. Endoscopic
retrograde biliary drainage (ERBD) tubes were inserted into
the future remnant liver in all patients with obstructive
jaundice.
After evaluation of tumor extension into the hepatic artery,
portal vein, and bile duct by preoperative imaging studies, two
cycles of chemotherapywith gemcitabine (600mg/m2 on days
7 and 21) plus S-1 (60 mg/m2 daily on days 1–21 every
4 weeks),5
, 6 followed by surgery, was administered to the
16 patients with local advanced perihilar cholangiocarcinoma
with (1) main, bilateral, or contralateral portal vein and/or
hepatic artery invasion with or without possible vascular re-
construction; or (2) invasion of the right side of the umbilical
portion (U portion) and the left side of the origin of the right
posterior portal vein (P portion); or (3) regional lymph node
metastasis. Of these, two patients received additional chemo-
radiotherapy because it was determined that curative intent
resection was impossible after completion of chemotherapy.
The total radiation dose for these two patients was 36 Gy
delivered in daily fractions of 1.8 Gy five times per week.
One of the patients was administered three infusions of
gemcitabine (800 mg/body) and the other was administered
four cycles of gemcitabine (1000 mg/body) plus cisplatin
(25 mg/body) on days 1 and 8 intravenously every 3 weeks.7
Based on preoperative imaging, we determined on which
side the hepatectomy should be performed. Right hepatecto-
my was applied to Bismuth type I, II, and IIIa tumors. Left
hepatectomy was applied to Bismuth type IIIb tumors. If a
tumor obviously extended over the second order biliary radi-
cles, such as Bismuth type IV tumors, trisectionectomy or
central bisectionectomy was selected. Combined with the
abovementioned anatomical criteria for hepatectomy, the type
of hepatectomy was determined using the following factors:
the indocyanine green retention rate at 15 min (ICGR15), the
hepatic uptake ratio of 99mTc-GSA scintigraphy at 15 min
(LHL15), and the future remnant liver volume using comput-
ed tomography (CT) volumetry.8 Portal vein embolization
(PVE) was indicated when the future remnant liver volume
was estimated as less than 40%.
For the patients with Bismuth type I and II perihilar chol-
angiocarcinoma, limited extrahepatic bile duct resection with-
out hepatectomy is occasionally performed, but our institution
usually employs right hepatectomy with caudate lobectomy,
based on previous studies. Ikeyama et al. performed a retro-
spective study on 31 consecutive patients who underwent re-
section of these types of tumors.9 R0 resection and survival
rates of patients who underwent right hepatectomy with cau-
date lobectomy (n = 18) were significantly better than those of
patients who underwent other types of resection (n = 13). In
that study, most patients did not have invasion of the right
hepatic artery, but the distance between the leading edge of
the cancer and the outer layer of the hepatic artery was 1 mm
in many patients. The authors suggested that the resected mar-
gin would have been cancer positive without combined resec-
tion of the right hepatic artery. Therefore, they recommend
right hepatectomy even when invasion of the right hepatic
artery cannot be demonstrated preoperatively by diagnostic
imaging. Two additional small studies also reported that out-
comes of limited resection except for those of right hepatec-
tomy with caudate lobectomy were unsatisfactory with low
curative resection rate and survival rate.10
, 11 Further evalua-
tion with larger sample sizes is required to justify right hepa-
tectomy with caudate lobectomy for Bismuth type I and II
perihilar cholangiocarcinoma.
Concept of THA for Perihilar Cholangiocarcinoma
The most common procedure for perihilar cholangiocarcino-
ma previously reported by Japanese surgeons is to first resect
the common bile duct above the pancreas and skeletonize the
hepatoduodenal ligament, followed by division of the hepatic
artery and portal vein of the future resected liver, hepatic pa-
renchymal transection along the demarcation line, and finally
transection of the hepatic bile duct of the future remnant
liver.12
, 13 In this procedure, the cut margin of the hepatic bile
duct is examined in the final stage.
Our THA procedure is very different from the previously
reported one in terms of when the hepatic bile duct transection
is performed. Our policy is to initially confirm a cancer-
negative margin of the hepatic bile duct. In THA, we first
performed partial hepatic parenchymal transection toward
the hepatic hilum to expose the hilar plate, followed by expo-
sure of the hepatic artery, portal vein, and bile duct in the
future remnant liver. Then, transection of the hepatic bile duct
is performed to confirm a cancer-negative margin, followed
by resection of the common bile duct above the pancreas and
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skeletonization of the hepatoduodenal ligament. Then, divi-
sion of the hepatic artery and portal vein of the future resected
liver is performed before transection of the residual hepatic
parenchyma.
Partial hepatic parenchymal transection using THA gives a
better surgical view of the cranial side of the hilar plate and
provides an improved surgical field for safe encircling and
taping of the proximal bile duct, portal vein, and hepatic artery
compared with performing these procedures without hepatic
parenchymal transection.
Surgical Procedures of THA for Perihilar
Cholangiocarcinoma
Under an inverted-T incision, careful exploration of peritoneal
dissemination and liver metastasis is performed. If there are no
obvious unresectable factors, taping of the hepatoduodenal
ligament using a Penrose drain and of the intrahepatic inferior
vena cava using sailor tape is first performed for the control of
accidental bleeding, and hepatic mobilization is started. After
dividing the bilateral coronary and triangular ligaments, the
short hepatic veins are divided to mobilize the caudate lobe
from the IVC.
The line of the middle hepatic vein (MHV) is marked on
the liver surface using electric cautery under ultrasonographic
(US) guidance, and the MHV is preserved on the side of the
future remnant liver. Following detachment of the gallbladder
from the gallbladder bed, the hepatic parenchyma transection
is started from the caudal-ventral edge of the Rex-Cantlie line
and advanced in the cranio-dorsal direction by using a
Cavitron ultrasonic surgical aspirator (CUSA) and monopolar
electrode irrigated with saline (vessel sealer device) under the
Pringle maneuver using a 15-min clamp and 5-min declamp.
When we encountered troublesome bleeding without formal
vascular control during THA procedure, we generally pressed
the bleeding site by gauze or grasp the bleeding vessel by the
forceps, and then performed Pringle maneuver to control
bleeding, followed by hemostasis using vessel sealing device
and/or suturing technique. The advancement of surgical
device and tissue sealing sheet enabled us to achieve enough
hemostasis at the hepatic cut surface.
For left hepatectomy, the left-side line of the MHV is
marked on the ventral liver surface. A straight line is also
marked on the dorsal liver surface from the caudal-ventral
edge of the Rex-Cantlie line to the root of the anterior
glissonial pedicle. After exposing the right-side hilar plate,
the right hepatic artery, portal branch, and hepatic bile duct
are carefully skeletonized and taped at the transected plane
(Fig. 1a, b). The shape of the partial hepatic parenchymal
transection plane is an isosceles triangle. Resection of the right
proximal hepatic bile duct is performed first. In many cases,
the right anterior and posterior sections of the bile duct are
resected separately. Frozen sections of the hepatic bile ducts
are immediately examined to confirm a cancer-negative mar-
gin of the proximal bile ducts (Fig. 1c, d). Thereafter, the
regional lymph nodes are resected along the common hepatic
artery and within the hepatoduodenal ligament while exposing
and taping the hepatic arteries, portal trunk, and common bile
duct. The common bile duct is transected above the pancreas.
The gallbladder and extrahepatic bile duct are reflected in a
cranio-ventral direction, and isolation of the portal trunk and
the proper hepatic artery is advanced up to the hepatic hilum.
After transecting the left hepatic artery and portal vein, the
right hepatic artery and portal vein are skeletonized to the
bifurcation of the right anterior and posterior sections of the
hepatic arteries and portal veins. When there is tumor involve-
ment of the portal vein in the future remnant side (Fig. 2a, b),
combined resection and reconstruction of the portal vein can
be performed under the wide surgical view obtained by the
THA. End-to-end anastomosis is performed by the
intraluminal suturing technique for the posterior wall and the
over-and-over method for the anterior wall using 6-0 vascular
sutures (Fig. 2c, d). At this point, the tumor is completely
separated from the residual liver, and the residual hepatic pa-
renchymal transection including the caudate lobe is per-
formed. When the hepatic artery in the future remnant side is
also involved, combined resection is performed and its end-to-
end anastomosis is performed with 9–0 vascular sutures under
a microscope after completion of the left hepatectomy with
caudate lobectomy (Fig. 3a, b).
For right hepatectomy, the right-side line of the MHV is
marked on the ventral liver surface. A straight line is also
marked on the dorsal liver surface from the caudal-ventral
edge of the Rex-Cantlie line to the root of the umbilical plate.
After exposing the left-side hilar plate, the left hepatic artery,
portal branch, and hepatic bile duct are carefully skeletonized
and taped at the transected plane (Fig. 4a, b). Resection of the
left hepatic bile duct is performed first. In many cases, the left
internal sectional bile duct and external sectional bile duct are
resected separately. A frozen section of the hepatic bile duct is
immediately examined to confirm a cancer-negative margin of
the proximal bile duct (Fig. 4c, d). Thereafter, the regional
lymph nodes are resected and the hepatic arteries, portal trunk,
and common bile duct are exposed and taped. The common
bile duct is transected above the pancreas. After transecting
the right hepatic artery and portal vein, the left hepatic artery
(and middle hepatic artery) and portal vein and left hepatic
artery are skeletonized to the right side of the umbilical plate.
When there is tumor involvement of the portal vein in the
future remnant side, combined resection and reconstruction
of the portal vein can be performed. At this point, the tumor
is completely separated from the residual liver, and the resid-
ual hepatic parenchymal transection including the caudate
lobe is performed. When the hepatic artery in the future rem-
nant side is also involved, combined resection is performed as
is its end-to-end anastomosis.
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The indications for portal vein and hepatic artery resection
include the following: (1) to enable taping of the proximal
portal vein and hepatic artery in the future remnant liver, (2)
to enable sufficient length of the proximal portal vein and
hepatic artery to perform end-to-end anastomosis, and (3) to
enable R0 resection. If necessary, the right external iliac vein




Fig. 2 Portal vein resection and
reconstruction in the middle of
left hepatectomy. a, b Tumor
invaded from left to main portal
vein. c, d Right portal vein
resection and reconstruction was
easily performed by using the
intraluminal suturing technique
for the posterior wall and the
over-and-over method for the
anterior wall using 6-0 vascular
sutures under the open and wide
surgical view after partial
hepatectomy. T tumor, RHA right
hepatic artery, LHA left hepatic
artery, PHA proper hepatic artery,
GDA gastroduodenal artery, PV
portal vein, RPV right portal vein,




Fig. 1 Transhepatic hilar
approach of left hepatectomy for
perihilar cholangiocarcinoma. a,
b The hepatic transection
progresses to the root of the
anterior glissonial sheath. After
completely exposing the planed
cutting glisson sheath, the hepatic
artery, portal branch, and plate
with proximal bile duct are
carefully divided and taped at the
transected plane. c, d Dissection
of sheath with proximal bile duct
is first performed and the frozen
sections of the hepatic bile ducts
are immediately examined to
confirm a cancer-negative margin
of the proximal bile ducts. RHA
right hepatic artery, RPV right
portal vein, RBD right bile duct
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When performing left hepatectomy, we occasionally en-
counter three bile duct stumps at the transection plate: the right
anterior inferior segmental bile duct (B5), right anterior supe-
rior segmental bile duct (B8), and posterior sectional bile duct.
During right hepatectomy, there are also two (or three) bile
duct orifices at the transected plate: the internal sectional bile
duct (B4) and external sectional bile duct (B2 + B3) (or inde-
pendently B4, B2, B3). In these cases, hepaticojejunostomy
with biliary stents in an antecolic Roux-en-Y fashion is per-
formed using either interrupted or continuous sutures with 6-0
absorbable monofilament threads. Especially when the bile
duct orifices are very small (less than 5 mm), 12 stitches are
sutured on the small anastomosis using the Pair-Watch
suturing technique.14
Results
Neoadjuvant chemotherapy based on GS therapy was per-
formed in 16 (69.6%) of the 23 patients (Table 1). In addition,
combined radiation therapy was also performed in two (8.7%)
patients. Hepatic resections were performed without any in-
traoperative complications. Several kinds of hepatectomy
with caudate lobectomy and extrahepatic bile duct resection
were performed as shown in Table 1: left hepatectomy in 12
patients (52.2%), left trisectionectomy in two patients (8.7%),
right hepatectomy in seven patients (30.5%), right
trisectionectomy in one patient (4.3%), and central
bisectionectomy in one patient (4.3%). A combined vascular
resection with reconstruction was performed in 14 patients
a b
c d
Fig. 4 Transhepatic hilar
approach of right hepatectomy for
perihilar cholangiocarcinoma. a,
b The hepatic transection
progresses to the root of the
umbilical plate. After completely
exposing the planned cutting
glisson sheath, the hepatic artery,
portal branch, and plate with
hepatic bile duct are carefully
divided and taped at the
transected plane. c, d Dissection
of sheath with proximal bile duct
is first performed and the frozen
sections of the hepatic bile ducts
are immediately examined to
confirm a cancer-negative margin
of the proximal bile ducts. LHA
left hepatic artery, LPV left portal
vein, LBD left bile duct
a b
Fig. 3 Hepatic artery resection and reconstruction after hepatectomy. a
Tumor invaded to right hepatic artery (RHA). b RHA resection and
reconstruction was performed under a microscope after completed liver
resection with caudate lobe. RHA right hepatic artery, GDA
gastroduodenal artery, RPV right portal vein
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(60.9%), including the portal vein alone in 11 patients and both
portal vein and hepatic artery in three patients. In addition, com-
bined pancreaticoduodenectomy was also performed in one pa-
tient. Median operation time was 600 min (range 382–728 min)
and median blood loss was 1789 ml (range 556–4978ml). In the
TNM staging system by the UICC (7th edition), pT stage was
identified in pT1 in one patient (4.3%), pT2a in four patients
(17.4%), pT2b in six patients (26.1%), pT3 in 10 patients
(43.5%), and pT4 in two patients (8.7%). Twelve patients
(52.5%) had regional lymph node metastasis (pN1) and two
patients (8.7%) had intrahepatic metastases (M1). The final
tumor stage was stage II in five patients (21.7%), IIIA in six
patients (26.1%), IIIB in 10 patients (43.5%), and IVB in two
patients (8.7%). R0 resections were performed in 17 (74.0%) of
the 23, including two patients with distant metastases. As shown
in Table 2, R1 margins were found in three patients (13.0%): the
proximal bile duct margin (HM) was positive in one patient and
the dissected margin (EM) was positive in two. R2margins were
found in three patients (13.0%): HM was positive in one and
intrahepatic metastasis was found in two. Regarding the frequen-
cy of bile duct resection required to achieve margin-negative
status of the HM (Fig. 5), 19 patients (82.7%) obtained margin-
negative status at the first bile duct resection. Carcinoma in situ
was found in one patient and invasive carcinoma in the other
three. Among these four patients, two patients (8.7%) finally
obtained margin-negative status after an additional bile duct re-
section. Therefore, 21 patients (91.3%) ultimately obtained
margin-negative status of the proximal bile duct. However, of
these, two patients were postoperatively diagnosed as dissected
margin (EM) positive and two patients also had intrahepatic me-
tastasis in the resected specimen. Therefore, 17 patients (74%)
actually achieved R0 resection (Table 2). When relating margin-
negative status of HM to Bismuth classification, the frequency of
margin-negative status at the first bile duct resection was 4/4
(100%) in type IIIa patients, 6/7 (85.7%) in type IIIb patients,
and 9/12 (75.0%) in type IV patients. The final frequency of
margin-negative status was also 4/4 (100%) in type IIIa patients,
7/7 (100%) in type IIIb patients, and 10/12 (83.3%) in type IV
patients. In terms of the postoperative course and prognosis of
patients with R1 or R2 resection, two patients who were diag-
nosed as EM1 positive after major hepatectomy with caudate
lobectomy are alive without recurrence at 43 and 28months after
operation, respectively. Of the two patients who were diagnosed
with intrahepatic metastasis in the resected specimen after left
hepatectomy with caudate lobectomy, one patient died at
9 months and the other patient is alive at 18 months after the
operation. Of the two patients who were intraoperatively diag-
nosed as HM positive, one was HM1 positive (invasive carcino-
ma) in both the B2 and B3 bile ducts even after additional resec-
tion and underwent right trisectionectomy with caudate lobecto-
my, because PVE was preoperatively performed. This patient
developed anastomotic stenosis of the hepaticojejunostomy at
6months and died at 16months after operation. The other patient
was HM2 positive (invasive carcinoma) in both anterior and
posterior sectional bile ducts even after additional resection and
underwent left hepatectomywith caudate lobectomy, because the
preoperatively estimated hepatic resection rate was less than
30%. This patient developed anastomotic stenosis of the
hepaticojejunostomy at 3 months and died at 28 months after
Table 1 Patients’ characteristics and clinicopathological features
Average age (years) 70 (51–87)
Gender (male/female) 13/10
Preoperative treatment 16 (69.6%)
Chemotherapy 14
Chemoradiotherapy 2




S1, 2, 3, 4/S1, 2, 3, 4, 5, 8 12 (52.2%)/2 (8.7%)
S1, 5, 6, 7, 8/S1, 4, 5, 6, 7, 8 7 (30.5%)/1 (4.3%)
S1, 4, 5, 8 1 (4.3%)
Combined vascular resection 14 (60.9%)
Portal vein alone 11
Portal vein and hepatic artery 3
Pancreatoduodenectomy 1
Operation time: median (range) 556 (383–728) min











Postoperative hospital stay: median (range) 44 (22–136) days
R0 complete resection, R1microscopic residual tumor resection, R2mac-
roscopic residual tumor resection or distant metastasis
Table 2 Residual tumor factors
Residual
tumor
Local factor Distant factor Total
pHM(+) pDM(+) pEM(+) pM1
R1 1 0 2 0 3 (13.0%)
R2 1 0 0 2 (IM) 3 (13.0%)
6 (26.0%)
pHM proximal bile duct margin, pDM distal bile duct margin, pEM dis-
sected margin, IM intrahepatic metastasis
J Gastrointest Surg (2017) 21:590–599 595
the operation. Clavien III or higher postoperative complications
occurred in 11 patients (45.8%) (Table 3). Among them, five
developed intra-abdominal abscesses due to bile leakage that
required percutaneous drainage. Two of these patients also de-
veloped ileus that required surgical treatment, followed by liver
failure due to the abscesses. Outflow blockage requiring stent
insertion at POD8, portal vein thrombosis following portal vein
resection and reconstruction requiring stent insertion at POD1,
and drainage of pleural effusion each occurred in one patient. The
median postoperative hospital stay was 44 days (range 22–
136 days). The disease-specific 3-year survival rate was 52.9%
(median survival time 52.4 months) (Fig. 6a). R status distribu-
tion (Fig. 6b) was 55.3%R0 and 41.7%R1/2with no statistically
significant difference (p = 0.349).
Discussion
The most important factor for achieving R0 resection for
perihilar cholangiocarcinoma is margin-negative status of the
remnant liver, including the proximal hepatic artery, portal
vein, and bile duct. The actual surgical procedure can be per-
formed in several ways. The THA technique first performs the
partial hepatic parenchymal transection toward the right-side
hilar plate for left hepatectomy or left-side hilar plate for right
hepatectomy to expose the hilar plate and decide the proximal
transected plane. After separating the proximal hepatic artery,
portal branch, and bile duct at the transected plane, the tran-
section of proximal bile duct is performed to confirm proximal
margin-negative status under a wide surgical view.
Advanced perihilar cholangiocarcinoma easily invades ma-
jor blood vessels including the hepatic artery and portal vein
because of its anatomical characteristics. Hepatobiliary sur-
geons frequently have to judge the necessity of combined
resection and reconstruction of the major blood vessels. In this
situation, the most critical aspect in achieving a safe resection
and reconstruction is whether or not encircling of the hepatic
artery and portal branch at the future remnant side can be
performed. If impossible, abandoning the curative resection
should be considered. THA provides a wide surgical view
and enables the surgeon to confirm the resectability and pos-
sibility of reconstruction of the major blood vessels early in
the operation.
To achieve R0 resection, the absence of residual tumor of
the proximal bile duct is one of the most crucial prognostic
factors.2 Preoperative imaging studies are usually used to de-
termine the type of hepatectomy and the cutting line of prox-
imal bile duct. Choi et al. reported that the accuracies of CT,
ERCP, and IDUS to evaluate the longitudinal extensions of
perihilar cholangiocarcinoma before biliary drainage were
66.6, 60, and 90%, respectively.15 However, once a biliary
catheter was inserted, the accuracy of IDUS in assessing lon-
gitudinal cancer extension declined to 71–72% due to bile
duct wall thickening due to the inflammatory change induced
by mechanical stimulation.16 In clinical practice, biliary cath-
eters have been inserted in most cases of perihilar cholangio-
carcinoma preoperatively. Therefore, in patients with perihilar
cholangiocarcinoma who have a hilar plate with inflammatory
change caused by the biliary catheter and obstructive
cholangitis, and/or with tumor invasion, our THA procedure
has the benefit of widely exposing the hilar plate without
touching the severe inflamed and/or tumor invasion areas. It
is also a useful technique to confirm the margin status of the
proximal bile duct under a clear surgical view early in surgery.
In patients with margin-positive hepatic proximal bile ducts,
additional bile duct resection is usually performed. However,
such limited resection of a margin-positive proximal bile duct
did not improve survival when compared with patients in
whom margin-negative proximal bile ducts was achieved at
the first bile duct resection, even when a margin-negative sta-
tus could be obtained with additional resections.17
, 18 In our


























Fig. 5 Flow diagram of residual
tumor status of proximal bile duct
margin according to the
frequency of bile duct resection.
*CIS carcinoma in situ
Table 3 Complication
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additional hepatic proximal bile duct resections. Unfortunately,
one patient died of liver metastasis at 13 months and the other
of local recurrence with liver metastasis at 33 months after
operation. Therefore, it is important to obtain cancer-free
margins of the hepatic proximal bile duct at the first resection.
With the THA procedure, margin-negative status of the resi-
dual hepatic proximal bile duct can be achieved in more than
80% of patients at the first resection, which compares favor-
ably to those in other leading centers.17
, 18 Our THA procedure
does not have an unfavorable comparison.1 The achievement
of margin-negative status for perihilar cholangiocarcinoma
might be dependent on selection of the relevant type of hepa-
tectomy based on precise preoperative evaluation of imaging
studies, but not on surgical procedure.
Margin-positive status of the proximal bile duct as a result
of periductal invasion and carcinoma in situ occurs in about
10% of perihilar cholangiocarcinoma surgeries, even if addi-
tional resections are performed. In the most common surgical
procedure for perihilar cholangiocarcinoma, the margin status
of the proximal bile duct is usually determined at the final step
of the procedure. In this situation, it is impossible to change
the type of hepatectomy because it has already occurred. In
THA, we confirm the margin status of the proximal bile duct
as one of the first steps. When a negative margin of the prox-
imal bile duct cannot be obtained even after additional resec-
tions, the THA procedure enables us to change the major
hepatectomy to an extensive hilar bile duct resection because
hepatectomy is not performed4
, 19 early in the operation.
During the same study period, we tried major hepatectomy
using the THA procedure in 24 patients with perihilar cholan-
giocarcinoma, of whom one (70-year-old female) could not
have a hepatectomy performed. In this case, the planned left
hepatectomy was changed to hilar bile duct resection early in
the operation, because severe periductal invasions of both the
anterior and posterior bile duct margin were found. The left
side of the bile duct was used for the hepaticojejunostomy
even though its ductal margin was positive. The patient devel-
oped anastomotic stenosis of the hepaticojejunostomy at
3 months and died at 15 months after the operation. On the
other hand, two patients were intraoperatively diagnosed as
HM positive. Therefore, the concept that THA enables us to
change the major hepatectomy to a hilar bile duct resection
early in the operation is not always applicable when the prox-
imal bile duct margin is intraoperatively diagnosed as cancer
positive, because hilar bile duct resection cannot be performed
in patients whose future resected liver has severe cancerous
invasion of the bile duct and hepatic vessels.
In the present study, we had to address whether neoadju-
vant chemotherapy or our THA procedure influenced the neg-
ative margin rate of the bile duct. There have been few reports
on the significance of preoperative or downsizing chemother-
apy or chemoradiotherapy for advanced biliary tract cancer.
Although the number of cases studied was small, Kato et al.
concluded that preoperative chemotherapy with gemcitabine
enabled the downsizing of initially unresectable locally ad-
vanced biliary tract cancer, with radical resection made possi-
ble in 8 (36.4%) of 22 patients. Four of these patients achieved
R0 resection.20 In the present study, 2 of the 23 patients were
diagnosed as cancer positive at the proposed cutting line of the
intrahepatic bile duct based on preoperative biopsy. Both pa-
tients obtained negative preoperative biopsies of the bile duct
at the cutting line after two cycles of chemotherapy. Finally,
R0 resection could be performed in both patients.
Accordingly, it is considered that preoperative chemotherapy,
but not our new technique, might have some effect to obtain
no cancerous proximal margin of the bile duct. However, fur-
ther study is needed.
In an attempt to avoid mortality, it is important for us to
perform a safe combined resection and reconstruction of the
portal vein and/or hepatic artery. According to a review article
for perihilar cholangiocarcinoma,1 portal vein resection and
reconstruction (0–44%) was more frequently performed com-
pared with hepatic artery reconstruction (0–18%). The timing
of portal vein reconstruction can be classified into three pe-
riods: before, in the middle of, and after hepatic parenchymal
transection. Portal vein resection and reconstruction before
hepatic parenchymal transection requires performing in a rel-
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reconstruction after hepatic parenchymal transection requires
continuing the hepatic resection procedure with limited move-
ment of the resection side of the liver because the bilateral
sides of the liver are connected by the portal vein. Therefore,
our procedure in which portal vein resection and reconstruc-
tion is performed in the middle of hepatic parenchymal tran-
section offers a wide surgical view, which overcomes the
faults of either alternative timing.
Regarding the significance of combined portal vein resec-
tion and reconstruction, three meta-analyses on combined por-
tal vein resection for hilar cholangiocarcinoma were recently
reported.21
–23 These studies demonstrated a survival benefit of
portal vein resection for hilar cholangiocarcinoma with portal
vein invasion but did not recommend routine portal vein re-
section unless necessary. Regarding combined hepatic artery
resection and reconstruction, there have been no meta-
analyses because of a lack of large study cohorts. Nagino
et al. retrospectively reviewed 50 patients with advanced chol-
angiocarcinoma who underwent hepatectomy with simulta-
neous portal vein resection and hepatic artery resection.
They reported that R0 resection was achieved in 33 (66.0%)
patients and the 5-year survival rate was 30.3%.24 Matsuyama
et al. also reviewed 44 patients with advanced cholangiocar-
cinoma who underwent hepatectomy with simultaneous he-
patic artery resection. They reported that R0 resection was
achieved in 35 (69.5%) patients and the 5-year survival rate
was 22.3%.25 These studies concluded that hepatic artery re-
section offered a survival benefit in selected patients.
However, the significance of hepatic artery resection for ad-
vanced hilar cholangiocarcinoma is still controversial towing
to increasedmorbidity andmortality without a proven survival
benefit or an improvement in the rate of clear margin
resections.23
, 26
THA for perihilar cholangiocarcinoma had some disadvan-
tages. One of the disadvantages was blood loss from the cut
surface of the precedent partial hepatic parenchyma resection.
However, the advancement of surgical devices and tissue
sealing sheets enabled us to achieve adequate hemostasis at
the hepatic cut surface. Another disadvantage was bile leakage
from the remnant proximal bile duct cut end early in the op-
eration. This issue was overcome by inserting soft tubes into
all hepatic proximal bile ducts to drain bile juice outside of the
surgical field. Another disadvantage was starting the partial
hepatic parenchymal resection without confirming the demar-
cation line, except in patients who underwent preoperative
portal vein embolization. Intraoperative US helps us to deter-
mine the hepatic resection line along the line of the preserved
major hepatic vein, but we experienced some patients who
developed ischemia along the cut margin of the residual liver
which required additional hepatic resection. This study itself
has a few limitations. Additionally, the patient cohort was
small and the observation period was short. Further evaluation
is needed to justify the use of this technique.
Conclusion
The THA procedure for perihilar cholangiocarcinoma is con-
sidered useful and practicable regardless of local tumor exten-
sion, enabling surgeons to determine tumor resectability and
perform safe resection and reconstruction of the major blood
vessels early in the operation under a wide surgical view.
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